Building access to the Regenstrief Institute is restricted through early 2021. More on our coronavirus precautions.
See our coronavirus precautions.
Shelley Johns, PsyD

A paper by a Regenstrief Institute and Indiana University School of Medicine research scientist in the highly influential journal, “Cancer,” was among the journal’s top 10 percent most-downloaded papers of the last year.

The study was a randomized controlled trial that found that acceptance and commitment therapy (ACT) helped cancer survivors cope with their fear that cancer would return.

Shelley Johns, PsyD, was the first author on the paper. She is a research scientist with Regenstrief’s Center for Health Services Research, an assistant professor and an adjunct associate professor of psychiatry at the IU School of Medicine, and a research scientist and a clinical health psychologist at Eskenazi Health.

The study is the first of its kind. Results showed that breast cancer survivors who received ACT showed significantly larger improvements in dealing with the fear of recurrence when compared to survivors who received other treatments. Fear of recurrence is very common in survivors of cancer, causing anxiety, depression and diminished quality of life. Up to 70 percent of breast cancer survivors report that the fear affects their daily life.

In ACT, therapists work with survivors to practice mindfulness, helping them pay attention to the present moment without letting fears about the future interfere with their quality of life.

The study compared the effect of ACT, survivorship education and enhanced usual care on fear of recurrence. The research team assessed the participants’ fear at the beginning of the study, immediately after the intervention, one month after, and then six months after. Each of the three groups showed reductions in the severity of their fear, but only ACT led to significant improvements at each evaluation, and the effect continued to grow as time went on.

In addition, the success of recruitment and retention rates in the study demonstrated that this treatment is feasible.

MEDIA CONTACTS:
John Erickson
Regenstrief Institute
prteam@regenstrief.org
(317) 643-2313
Cindy Fox Aisen
Regenstrief Institute
caisen@regenstrief.org
(317) 843-2275

Related News

Mar 05, 2021 • News
More than 2/3 of Indiana nursing home staff would take COVID-19 vaccine
Educating staff is crucial for increasing uptake and achieving desired results In a study conducted shortly before COVID-19 vaccines became available in the U.S., more than two-thirds of nursing home and assisted living staff in Indiana indicated willingness to receive a vaccine immediately or in the future. The study was led by researchers from Regenstrief Institute, Indiana University and…
Continue Reading >
Mar 02, 2021 • News
Second online survey launched by Regenstrief, IU to help gather COVID-19 data
Data shows willingness to get vaccine, reaches at-risk population   Regenstrief Institute and Indiana University launched a second online survey to gather data about COVID-19 symptoms, behaviors, and vaccine attitudes following the success of a pilot project. The questionnaire allows researchers to gather large quantities of data from across the U.S. quickly.   The pilot survey went online in April 2020 with questions about individuals’ COVID-19 symptoms, general location and travel history. It was distributed via banner ads on…
Continue Reading >